A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
This is a phase 1/2 multicentre study to assess the safety and effectiveness of brentuximab
vedotin and bendamustine, when given together, in patients with Hodgkin Lymphoma or
Anaplastic Large Cell Lymphoma (ALCL) that has either returned or did not respond to initial
treatment(s). Patients will be accrued at Columbia University Medical Centre (CUMC) and at
two subsites in Canada.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society